UK markets open in 5 hours 25 minutes

Celyad SA (CYAD)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.9400-0.0600 (-1.20%)
At close: 4:00PM EDT
Sign in to post a message.
  • J
    James
    Celyad Highlights Abstracts from mCRC Clinical Program Released for SITC 34th Annual Meeting
    www.globenewswire.com
  • J
    James
    Future development of relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) program to be underpinned by proprietary...
    Future development of relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) program to be underpinned by proprietary...
    www.globenewswire.com
  • J
    James
    Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting
    www.globenewswire.com
  • J
    James
    In an interview with Targeted Oncology, Frédéric Lehmann, MD, discussed the results for the alloSHRINK trial that were presented at the SITC 34<sup>th</sup>Annual Meeting. The allogenic CAR T-cell therapy, CYAD-101, in association
    In an interview with Targeted Oncology, Frédéric Lehmann, MD, discussed the results for the alloSHRINK trial that were presented at the SITC 34<sup>th</sup>Annual Meeting. The allogenic CAR T-cell therapy, CYAD-101, in association
    www.targetedonc.com
  • K
    Kris
    Time for the good news show to start...
  • J
    Josh Billionaire
    Got FDA clearance today! Let's go
  • M
    Maxime
    Great news this weekend and yet no respons on the market , sad !!!
  • M
    Mo
    $ONVO conversation
    Key events next week - healthcare https://seekingalpha.com/news/3352380?source=ansh $OVID, $EOLS, $AGN, $JNJ, $NTLA, $QURE, $RCKT, $BOLD, $VYGR, $EDIT, $CYAD, $CLLS, $RXII, $BCLI, $ONVO, $VCYT, $EBIO, $URGN, $GTXI, $KDMN, $VRNA

    ONVO
    Noteworthy events during the week of May 13 - 19 for healthcare investors:Sunday (5/13): 14th Eilat Conference on New Antiepileptic Drugs and Devices, Madrid, Spain (4 days). Ovid Therapeutics (NASDAQ
    Noteworthy events during the week of May 13 - 19 for healthcare investors:Sunday (5/13): 14th Eilat Conference on New Antiepileptic Drugs and Devices, Madrid, Spain (4 days). Ovid Therapeutics (NASDAQ
    seekingalpha.com
  • K
    Katherine
    MONT-SAINT-GUIBERT, Belgium, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced an update on its operational developments for the third quart... Great article here about CYAD https://marketwirenews.com/news-releases/celyad-announces-third-quarter-2019-financial-result-5983770697648630.html?i=c
    MONT-SAINT-GUIBERT, Belgium, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage.
    MONT-SAINT-GUIBERT, Belgium, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage.
    marketwirenews.com
  • T
    Taylor
    MONT-SAINT-GUIBERT, Belgium, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that the Company has received #$%$2.5 million in non-dilu... Read this article on CYAD https://marketwirenews.com/news-releases/celyad-receives-additional-euro2-5-million-in-non-di-8344973463292218.html?i=c
    MONT-SAINT-GUIBERT, Belgium, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage.
    MONT-SAINT-GUIBERT, Belgium, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage.
    marketwirenews.com
  • M
    Maxime
    looks more like an implosion then a explosion to me , what on earth happening with celyad , already a haircut of more then 50% this year
  • b
    barbermh
    Now if big pharma is paying around $10B for car-t companies, this could be their problem we need to get out of oncology

    READ THIS:

    Dr. Mary Tagliaferri - Nektar

    “Yeah. We have shown an update from our dose escalation patients for first line melanoma, first line RCC and non-small cell lung cancer, and this pattern, we have actually seen to be consistent across all three of these solid tumor types. And from a biological perspective, it makes sense that Nektar-214 would have this robust effect in all tumor types, because the mechanism provides for new antigen specific T-cells to be generated every 21 days and that’s why we see this effect over time in contrast to CAR-T where you see a very high rate of relapse after six months of treatment, because all those T-cells are now gone, in contrast NKTR-214 generates this new replenishment of these antigen specific piece T-cells every 21 days, which is why we see this ongoing tumor regression and tumor reduction with ongoing treatment.”
  • H
    Hrdwkgdog
    The CAR-T cell treatment...........if ever completed and commercialized at a price nobody can afford.......will be finalized probably by MD Anderson..........and not CYAD. At this point.......clinical trials are being established...........and nobody is anywhere where it some day could be.......meaning to be administered to cancer patients as an approved treatment.
  • B
    Bloodmoon
    FOLLOW THE MONEY.
    James you are appreciated.
  • S
    Simon
    Very nice buy here. Huge potential, investor presentations 7-9 november with update clincal results and also beginning of december another presentation so a lot newsflow.
    Stock could easily double.
  • b
    barbermh
    Looking for a little more info on this one, I guess this isn't the place for that!
  • H
    Hrdwkgdog
    Wow.............-2- shares traded today..........Is that a record ?
  • a
    alles kan beter
    nice pr today...
  • H
    Hrdwkgdog
    CLLS/CLXT just diluted ~53%, and now CYAD is diluting ~26%. What is it with those EU companies ? Can't they find E in Europe ?
  • K
    Ketchdeal
    So. At 4:46 p.m. Celyad posts a news release that says they will be selling 1.8 million shares, and possibly 270k more to the underwriters. At 4:47 Celyad posts a first quarter business update that states: "The company ended the quarter with #$%$25.1 million in cash, cash equivalents and short-term investments. Use of cash over the first quarter of 2018 amounted to #$%$8.8 million, in line with expectations. The company confirms that existing cash and cash equivalents and short term investments are sufficient to fund operating expenses and capital expenditure requirements, based on the current scope of activities, until the end of Q1 2019."I suppose if they do not expect to release any worthwhile news for the next two quarters, they may as well strike while the iron is room temperature. So my takeaway is management considers their stock as dead money, and shareholders as suckers.Good luck with that.